rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2016-12-6-743-748rpcardio-1379Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯHEART FAILURE AND DIABETES MELLITUS: SELECTED ISSUES OF ETIOLOGY AND PATHOGENESIS, PROGNOSIS AND TREATMENTСЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ И САХАРНЫЙ ДИАБЕТ: ОТДЕЛЬНЫЕ ВОПРОСЫ ЭТИОПАТОГЕНЕЗА, ПРОГНОЗА И ЛЕЧЕНИЯМардановБ. У.MardanovB. U.

Марданов Баходир Умаркулович – кандидат медицинских наук, врач-кардиолог сосудистого центра Домодедовской центральной городской больницы; старший научный сотрудник лаборатории по разработке междисциплинарного подхода в профилактике хронических неинфекционных заболеваний отдела профилактики коморбидных состояний ГНИЦ ПМ.

Bahodir U. Mardanov – MD, PhD, Cardiologist of Vascular Center, Domodedovo Central City Hospital; Senior Researcher, Laboratory for Development of Interdisciplinary Approach in Prevention of Chronic Non-Communicable Diseases, Department of Comorbid Conditions Prevention, State Research Centre for Preventive Medicine. 

Pirogova ul. 9, Domodedovo, Moscow Region., 142005 

mb_sky@inbox.ruКорнееваМ. Н.KorneevaM. N.

Корнеева Марина Николаевна – кандидат медицинских наук, младший научный сотрудник лаборатории по разработке междисциплинарного подхода в профилактике хронических неинфекционных заболеваний отдела профилактики коморбидных состояний 

 

Marina N. Korneyeva – MD, PhD, Junior Researcher, Laboratory for Development of Interdisciplinary Approach in Prevention of Chronic Non-Communicable Diseases, Department of Comorbid Conditions Prevention

АхмедоваЭ. Б.AkhmedovaE. B.

Ахмедова Эсмеральда Биннатовна – младший научный сотрудник лаборатории по разработке междисциплинарного подхода в профилактике хронических неинфекционных заболеваний отдела профилактики коморбидных состояний

Esmeralda B. Akhmedova – MD, Junior Researcher, Laboratory for Development of Interdisciplinary Approach in Prevention of Chronic Non-Communicable Diseases, Department of Comorbid Conditions Prevention

Домодедовская центральная городская больница; Государственный научно-исследовательский центр профилактической медициныРоссияDomodedovo Central City Hospital; State Research Centre for Preventive MedicineRussian FederationГосударственный научно-исследовательский центр профилактической медициныРоссияState Research Centre for Preventive MedicineRussian Federation201607012017126743748Copyright © Mardanov B.U., Korneeva M.N., Akhmedova E.B., 20172017Марданов Б.У., Корнеева М.Н., Ахмедова Э.Б.Mardanov B.U., Korneeva M.N., Akhmedova E.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1379

This review is devoted to the study of issues relating to the features of associated course of chronic heart failure (CHF) and diabetes mellitus (DM). The modern views on the epidemiology, pathogenesis of DM and CHF are systematized. The pathogenesis of diabetic cardiomyopathy is described in details. The results of the well-known studies that show the negative impact of DM on CHF prognosis are presented. The principles of CHF pathogenetic therapy in patients with DM including the role of neurohormonal modulators are analyzed. The results of multicenter studies in patients with CHF and concomitant DM type 2 show that almost all first-line drugs recommended for CHF treatment are effective in patients with DM.

Статья посвящена изучению вопросов, касающихся особенностей сопряженного течения хронической сердечной недостаточности (ХСН) и сахарного диабета (СД). Систематизированы современные взгляды на вопросы эпидемиологии, патогенеза СД и ХСН. Более подробно описывается патогенез диабетической кардиомиопатии. Приведены результаты известных исследований, где показано негативное влияние СД на прогноз ХСН. В разделе, посвященном принципам патогенетической терапии ХСН у больных СД, анализируется роль нейрогуморальных модуляторов. По результатам многоцентровых исследований в подгруппах больных ХСН и сопутствующим СД 2 типа показано, что практически все препараты первой линии, рекомендованные для лечения сердечной недостаточности, демонстрируют свою эффективность и у больных диабетом.

хроническая сердечная недостаточностьсахарный диабетпрогнозchronic heart failurediabetesprognosisReferencesMamedov M.N., Mardanov B.U., Dudinskaya E.N. Heart failure patients with diabetes: diagnosis, treatment, prevention. Moscow: Fond "Kardioprogress"; 2015 (In Russ.) [Мамедов М.Н., Марданов Б.У., Дудинская Е.Н. Сердечная недостаточность у больных сахарным диабетом: диагностика, лечение, профилактика. М.: Фонд «Кардиопрогресс»; 2015].Mamedov M.N., Mardanov B.U., Dudinskaya E.N. Heart failure patients with diabetes: diagnosis, treatment, prevention. Moscow: Fond "Kardioprogress"; 2015 (In Russ.) [Мамедов М.Н., Марданов Б.У., Дудинская Е.Н. Сердечная недостаточность у больных сахарным диабетом: диагностика, лечение, профилактика. М.: Фонд «Кардиопрогресс»; 2015].IDF Diabetes Atlas. Sixth edition, 2015. Available at: http://www.diabetesatlas.org/resources/2015atlas.html. Accessed by October 15, 2016.IDF Diabetes Atlas. Sixth edition, 2015. Available at: http://www.diabetesatlas.org/resources/2015atlas.html. Accessed by October 15, 2016.National guidelines on the diagnosis and treatment of chronic heart failure (fourth revision). Serdechnaya Nedostatochnost'. 2013; 81 (7): 379-472. (In Russian) [Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (четвертый пересмотр). Сердечная Недостаточность. 2013; 81(7):379-472].National guidelines on the diagnosis and treatment of chronic heart failure (fourth revision). Serdechnaya Nedostatochnost'. 2013; 81 (7): 379-472. (In Russian) [Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (четвертый пересмотр). Сердечная Недостаточность. 2013; 81(7):379-472].Kengne AP, Turnbull F, MacMahon S. The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock. Prog Cardiovasc Dis. 2010;53:45-51. doi: 10.1016/j.pcad.2010.02.010.Kengne AP, Turnbull F, MacMahon S. The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock. Prog Cardiovasc Dis. 2010;53:45-51. doi: 10.1016/j.pcad.2010.02.010.Bjorck LM, Lanitis M, Lappas G, et al. Mortality Trends 1987 to 2004 in 404,480 Hospitalized Heart Failure Patients with and without Diabetes. Circulation. 2012;125:AP208 (Abstract).Bjorck LM, Lanitis M, Lappas G, et al. Mortality Trends 1987 to 2004 in 404,480 Hospitalized Heart Failure Patients with and without Diabetes. Circulation. 2012;125:AP208 (Abstract).He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANESI epidemiologic follow-up study. Arch Intern Med. 2001;161:996-1002. doi: 10.1001/archinte.161.7.996.He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANESI epidemiologic follow-up study. Arch Intern Med. 2001;161:996-1002. doi: 10.1001/archinte.161.7.996.Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55:2154-62. doi: 10.1007/s00125-012-2579-0.Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55:2154-62. doi: 10.1007/s00125-012-2579-0.Wang Y, Negishi T, Negishi K, et al. Clinical Prediction of Incident Heart Failure in Type 2 Diabetes Mellitus in 507,637 Patients: a Systematic Review and Meta-analysis. Circulation. 2014;130:A17157. doi: 10.1016/j.diabres.2015.01.011.Wang Y, Negishi T, Negishi K, et al. Clinical Prediction of Incident Heart Failure in Type 2 Diabetes Mellitus in 507,637 Patients: a Systematic Review and Meta-analysis. Circulation. 2014;130:A17157. doi: 10.1016/j.diabres.2015.01.011.Nielson С, Lange T. Blood Glucose and Heart Failure in Nondiabetic Patients. Diabetes Care March. 2005; 28:3607-611. doi: 10.2337/diacare.28.3.607.Nielson С, Lange T. Blood Glucose and Heart Failure in Nondiabetic Patients. Diabetes Care March. 2005; 28:3607-611. doi: 10.2337/diacare.28.3.607.Vaur L, Gueret P, Lievre M, et al. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, Cardiovascular Events and Ramipril) study. Diabetes Care. 2003;26:855-860. doi: 10.2337/diacare.26.3.855.Vaur L, Gueret P, Lievre M, et al. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, Cardiovascular Events and Ramipril) study. Diabetes Care. 2003;26:855-860. doi: 10.2337/diacare.26.3.855.Iribarren C, Karter AJ, Go AS. et al. Glycemic Control and Heart Failure Among Adult Patients With Diabetes. Circulation. 2001; 103:2668-73. doi: 10.1161/01.CIR.103.22.2668.Iribarren C, Karter AJ, Go AS. et al. Glycemic Control and Heart Failure Among Adult Patients With Diabetes. Circulation. 2001; 103:2668-73. doi: 10.1161/01.CIR.103.22.2668.Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11(1):31-39. doi: 10.1007/s11154-010-9131-7.Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11(1):31-39. doi: 10.1007/s11154-010-9131-7.Bell DS. Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? Diabetes Care. 1995;18:708-14.Bell DS. Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? Diabetes Care. 1995;18:708-14.Kosiborod M, Inzucchi SE, Spertus JA et al. Elevated Admission Glucose and Mortality in Elderly Patients Hospitalized With Heart Failure. Circulation. 2009;119:1899-907. doi: 10.1161/CIRCULATIONAHA. 108.821843.Kosiborod M, Inzucchi SE, Spertus JA et al. Elevated Admission Glucose and Mortality in Elderly Patients Hospitalized With Heart Failure. Circulation. 2009;119:1899-907. doi: 10.1161/CIRCULATIONAHA. 108.821843.Domanski M, Krause-Steinrauf H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42:914-22. doi: 10.1016/S07351097(03)00856-8.Domanski M, Krause-Steinrauf H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42:914-22. doi: 10.1016/S07351097(03)00856-8.Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107:1291-6. doi: 10.1161/01.CIR.0000054611.89228.92.Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107:1291-6. doi: 10.1161/01.CIR.0000054611.89228.92.Ryden L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J. 2000;21:1967-78. doi: 10.1053/euhj.2000.2311Ryden L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J. 2000;21:1967-78. doi: 10.1053/euhj.2000.2311Zuanetti G, Latini R, Maggioni A, et al. Effect of the ACE Inhibitor Lisinopril on Mortality in Diabetic Patients With Acute Myocardial Infarction: Data From the GISSI-3 Study. Circulation. 1997;96:423945. doi: 10.1161/01.CIR.96.12.4239Zuanetti G, Latini R, Maggioni A, et al. Effect of the ACE Inhibitor Lisinopril on Mortality in Diabetic Patients With Acute Myocardial Infarction: Data From the GISSI-3 Study. Circulation. 1997;96:423945. doi: 10.1161/01.CIR.96.12.4239EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet. 1998; 351: 28-31. doi: 10.1016/S0140-6736(97)06209-0EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet. 1998; 351: 28-31. doi: 10.1016/S0140-6736(97)06209-0Gerstein HC. Diabetes and the HOPE study: implication for macrovascular and microvascular disease. Int S Clin Pract. 2001;117(suppl.):8-12.Gerstein HC. Diabetes and the HOPE study: implication for macrovascular and microvascular disease. Int S Clin Pract. 2001;117(suppl.):8-12.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000;342:14553. doi: 10.1056/NEJM200001203420301The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000;342:14553. doi: 10.1056/NEJM200001203420301Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592.Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592.Kunz R, Friedrich C, Wolbers M, Mann J. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med. 2008; 148:30-48. doi:10.7326/0003-4819-148-1-200801010-00190Kunz R, Friedrich C, Wolbers M, Mann J. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med. 2008; 148:30-48. doi:10.7326/0003-4819-148-1-200801010-00190Deedwania PC, Giles TD, Klibaner M, et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J. 2005;149:15967. doi: 10.1016/j.ahj.2004.05.056Deedwania PC, Giles TD, Klibaner M, et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J. 2005;149:15967. doi: 10.1016/j.ahj.2004.05.056Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21. doi: 10.1056/NEJMoa1009492.Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21. doi: 10.1056/NEJMoa1009492.Pitt B, Anker SD, Bohm M. Rationale and design of Mineralocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015;17(2):224-32. doi: 10.1002/ejhf.218.Pitt B, Anker SD, Bohm M. Rationale and design of Mineralocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015;17(2):224-32. doi: 10.1002/ejhf.218.Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J. 2013;34(39):3035-87. doi:10.1093/eurheartj/eht108Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J. 2013;34(39):3035-87. doi:10.1093/eurheartj/eht108

The authors declare that there are no conflicts of interest present.